Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: 5-year results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial
Eggermont, A. M. M. Kicinski, M. Blank, C. U. Mandala, M. Long, G. V. Atkinson, V. G. Dalle, S. Haydon, A. M. Meshcheryakov, A. Khattak, A.
Eggermont, A. M. M.
Kicinski, M.
Blank, C. U.
Mandala, M.
Long, G. V.
Atkinson, V. G.
Dalle, S.
Haydon, A. M.
Meshcheryakov, A.
Khattak, A.
Citations
Altmetric:
Abstract
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Eggermont AMM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson VG, et al. Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: 5-year results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial. Annals of Oncology. 2022 Sep;33(7):S912-S3. PubMed PMID: WOS:000866211601075.